GlassScriptPhysician profile
Theodora Squire
NPI 1417591660
$11,907.04
in general payments reported to CMS, 2019-2025
33 companies · $3,904 in 2025
The $3,904 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $81.51 · 2022: $2,672 · 2023: $2,469 · 2024: $2,781 · 2025: $3,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,716 · Education: $95.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,716.24 |
| Education | $95.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,009.43 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,374.17 | 2022-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $1,234.54 | 2023-2025 | Tremfya, Stelara |
| Celgene Corporation | $664.35 | 2022-2024 | Zeposia |
| Pfizer INC. | $524.31 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $459.18 | 2022-2023 | Zeposia |
| Madrigal Pharmaceuticals | $444.37 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $399.24 | 2022-2025 | |
| Ardelyx, INC. | $360.83 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $347.59 | 2022-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $280.15 | 2024-2025 | Iqirvo, Bylvay |
| Gilead Sciences, INC. | $254.28 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $250.81 | 2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $248.80 | 2024-2025 | Omvoh |
| Medtronic, INC. | $181.29 | 2022-2023 | Gi Genius |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $176.13 | 2022-2023 | |
| Celltrion USA INC. | $152.11 | 2024-2025 | Zymfentra, Vegzelma |
| Ironwood Pharmaceuticals, INC | $148.43 | 2022-2024 | Linzess |
| Ethicon US, LLC | $106.66 | 2025 | Linx Reflux Management System |
| Daiichi Sankyo INC. | $76.81 | 2022-2023 | Injectafer |
| Ferring Pharmaceuticals INC. | $58.36 | 2022-2023 | Rebyota |
| Vivus LLC | $55.00 | 2024 | Qsymia |
| Phathom Pharmaceuticals, INC. | $54.99 | 2023-2024 | Voquezna |
| Aimmune Therapeutics, INC. | $53.96 | 2025 | Zenpep |
| Fresenius Kabi USA, LLC | $49.54 | 2023 | Idacio, Volumat Mc Agilia US |
| Braintree Laboratories, INC. | $44.96 | 2022-2025 | Sutab, Suflave |
| Pharmacosmos Therapeutics INC. | $31.30 | 2023 | Monoferric |
| Amgen INC. | $27.46 | 2023 | Amjevita, Avsola |
| Alexion Pharmaceuticals, INC. | $24.02 | 2025 | Ultomiris |
| Novo Nordisk INC | $20.96 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $19.35 | 2023 | Givlaari |
| Organon LLC | $19.23 | 2022 | |
| Intercept Pharmaceuticals, INC. | $18.99 | 2023 | Ocaliva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodora Squire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.